Loading...
XWAR
PHR
Market cap9mUSD
Jul 09, Last price  
3.13PLN
1D
0.00%
1Q
-4.57%
Jan 2017
-82.28%
IPO
-87.10%
Name

Pharmena SA

Chart & Performance

D1W1MN
XWAR:PHR chart
P/E
—
P/S
22.11
EPS
—
Div Yield, %
27.16%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-30.79%
Revenues
2m
+488.43%
3,809,8466,379,5497,704,3868,778,3819,130,00014,138,00014,129,00017,473,00015,914,00012,511,00013,040,00011,099,0009,933,00015,213,000299,0009,837,000268,0001,577,000
Net income
-3m
L+119.41%
611,360771,541123,730608,997-4,100,000-2,843,000-4,086,000-3,616,000-1,664,000-2,389,000-444,000-9,573,000-6,891,000-4,592,000-1,570,00028,941,000-1,262,000-2,769,000
CFO
-3m
L+7.66%
000666,906-4,054,000-3,836,000-5,751,000-4,175,000-950,000619,0003,613,000-13,146,000-2,243,000-3,225,0001,819,00033,032,000-2,531,000-2,725,000
Dividend
Sep 10, 20262.36 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.
URL
https://www.pharmena.eu/
IPO date
Aug 25, 2008
Employees
24
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT